|March 4, 2014
Media Contact: Jenn Meale
Phone: (850) 245-0150
|en Español||Print Version||Tweet|
TALLAHASSEE, Fla.—Attorney General Pam Bondi announced today that Florida, as part of a national settlement against Omnicare, Inc., has recovered nearly $70,000. The settlement resolves allegations that Omnicare violated federal and state law, including the Federal False Claims Act, the Federal Anti-Kickback Statute, and certain states’ false claims acts, with respect to the prescription drug Aranesp, a drug used for patients with chronic kidney disease.
Allegedly, Omnicare solicited and received payment from Amgen, Inc. in the form of purported discounts, purported market-share rebates, grants, honoraria, speaker fees, consulting services, dinners, travel, or fees for the purchase of data, and that this payment was solicited and received in exchange for influencing health care providers’ selection and use of Aranesp. Due to this alleged conduct, false and fraudulent claims for Aranesp were submitted to state Medicaid programs for reimbursement.
This settlement covers the qui tam action United States et al., ex rel. Frank Kurnik v. Amgen, Inc., et al. (Civil Action No. 3:11-cv-01464-JFA), filed in the United States District Court for South Carolina.
The Attorney General’s Medicaid Fraud Control Unit investigates cases of fraud committed upon the Medicaid program by providers and program administrators. The MFCU investigates a diverse mix of health care providers, including: doctors, dentists, psychologists, home health care companies, pharmacies, drug manufacturers, laboratories and more. The MFCU often investigations the pharmaceutical industry based on whistleblower filings pursuant to the Florida False Claims Act.